PROCEPT BioRobotics Corp 8-K

What Happened
PROCEPT BioRobotics Corporation announced on March 5, 2026 that its Board increased in size from eight to nine members and appointed Daniel Puckett as a Class III director to fill the vacancy. Mr. Puckett was also appointed to the Board’s Audit Committee and was determined to be an “independent director” under SEC and Nasdaq rules. His initial term expires at the Company’s 2027 annual meeting of stockholders.

Key Details

• Board size increased from 8 to 9 members; appointment effective March 5, 2026.
• Daniel Puckett will serve as a Class III director with term ending at the 2027 annual meeting.
• Appointed to the Audit Committee and deemed independent under SEC and Nasdaq standards.
• Background: former CFO of Shockwave Medical (Apr 2016–Feb 2024); prior CFO roles at Counsyl and Ariosa Diagnostics; MBA (University of San Francisco) and B.A. in Accounting (Washington State University).
• Compensation and indemnification: will receive the same compensation as other non-employee directors per the Company’s proxy (filed Apr 25, 2025) and will enter the Company’s standard indemnification/advancement agreement. No related-party transactions or arrangements to report under Item 404(a) were disclosed.

Why It Matters
This is a governance update that adds an experienced finance executive to PROCEPT’s Board and its Audit Committee—roles that oversee financial reporting and controls. Investors should view the appointment as a potential strengthening of financial oversight given Mr. Puckett’s CFO background. The filing confirms independence, standard director compensation, and no reportable conflicts, which are relevant to corporate governance and board composition assessments.